Long-term trends in the clinical management and outcomes of patients with gastroesophageal cancer in Norway
Open Access
- 15 April 2025
- journal article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 540-549
Abstract
Background and purpose: Gastroesophageal cancers are highly prevalent internationally, with many patients diagnosed with metastatic disease, leading to challenging treatment and poor survival. This study uses real-world evidence from a population-level database to describe demographics, clinical characteristics, initial treatment patterns, and survival for patients with gastroesophageal cancer in Norway. Material and methods: Individual patient data was sourced from the Cancer Registry of Norway for patients diagnosed with oesophageal squamous cell carcinoma (ESCC), oesophageal adenocarcinoma (EAC), gastroesophageal junction cancer (GEJC), and gastric cancer from 2001 to 2021, with follow-up from diagnosis to death or last follow-up. Treatment patterns were captured from 2010 to 2022, defined as curative or palliative based on surgery, chemotherapy, and radiotherapy. Results and interpretation: The cohort included 14,334 Norwegian patients with gastroesophageal cancer; predominantly male, mean age 69–73 years, with a median follow-up of 9–11 months across cancer subtypes. Approximately 40% of patients received curative treatment, and multi-modality treatments increased for EAC, GEJC, and ESCC. Median survival ranged from 6 to 11 months for patients treated palliatively, and 17–95 months for those treated with curative intent. Interestingly, median survival was higher for patients with EAC and GEJC treated with neoadjuvant chemotherapy (86.1 and 75.1 months) versus neoadjuvant chemoradiotherapy (49.1 and 42.1 months), which was confirmed by a multivariate Cox regression model adjusted for age, sex, and disease stage. This study demonstrates that multimodal treatment strategies, consisting of chemotherapy and surgery, may be associated with improved survival outcomes for gastroesophageal cancers. Future studies are required to identify optimum treatment strategies for gastroesophageal cancer subtypes.Keywords
This publication has 24 references indexed in Scilit:
- Survival and Treatment Patterns in Stage II to III Esophageal CancerJAMA Network Open, 2024
- Survival in gastric and esophageal cancers in the Nordic countries through a half centuryCancer Medicine, 2023
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: A population-based modelling studyeClinicalMedicine, 2022
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialThe Lancet, 2019
- Esophageal cancer: Risk factors, genetic association, and treatmentAsian Journal of Surgery, 2018
- Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trialThe Lancet Oncology, 2018
- Chemotherapy for advanced gastric cancerCochrane Database of Systematic Reviews, 2017
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trialThe Lancet Oncology, 2015